Expression of Estrogen Receptors (ER), Progesterone Receptors (PR) and HER-2/neu receptors in Endometrial Carcinoma and their associations with histological types, grades and stages of the tumor

被引:11
|
作者
Waqar, Samina [3 ]
Khan, Saleem Ahmad [1 ]
Sarfraz, Tariq [3 ]
Waqar, Saba [2 ]
机构
[1] Mil Hosp, Army Med Coll, Dept Hematol, Rawalpindi, Pakistan
[2] Mil Hosp, Army Med Coll, Dept Dent Mat, Rawalpindi, Pakistan
[3] Mil Hosp, Army Med Coll, Dept Histopathol, Rawalpindi, Pakistan
关键词
Endometrial Carcinoma; Estrogen Receptors; Her-2/Neu; Progesterone Receptors; UTERINE SEROUS CARCINOMA; AGGRESSIVE VARIANT; TARGETED THERAPY; CANCER; OVEREXPRESSION; ADENOCARCINOMA; AMPLIFICATION; HER2/NEU;
D O I
10.12669/pjms.342.13637
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To study and detect immunohistochemical expression of Estrogen Receptors, Progestrone Receptors and HER-2/neu Receptors in Endometrial Carcinoma (EC) and to find their associations with histological types, grades and stages of the tumor. Methods: A cross sectional study of one year duration from January 2016 to January 2017 was conducted at Histopathology department of Army Medical College, Rawalpindi. A non-probability purposive sampling technique was used to include 56 cases of EC. The specimens were tested for ER, PR and HER-2/neu expression using immunohistochemical analysis. Data was analyzed in SPSS and the significance of association of expression of the receptors with histological types, grades and stages of the tumor was assessed. Results: Significant association of Her-2/neu overexpression with histological types and grades of EC was seen, whereas the association of ER and PR expression with histological types, grades and stage of EC was statistically insignificant. Conclusion: It is suggested that EC showing over expression of HER2/neu with immunohistochemistry may be treated with anti HER-2/neu treatment with better chances of survival and decreased post-treatment morbidity.
引用
收藏
页码:266 / 271
页数:6
相关论文
共 38 条
  • [31] Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast
    Steinman, Sharon
    Wang, Jianmin
    Bourne, Patricia
    Yang, Qi
    Tang, Ping
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2007, 37 (02) : 127 - 134
  • [32] Correlation of human epidermal growth factor receptor 2 (HER-2/neu) receptor status with hormone receptors Oestrogen Receptor, Progesterone Receptor status and other prognostic markers in breast cancer: an experience at tertiary care hospital in Karachi
    Mujtaba, Shafaq
    Haroon, Saroona
    Faridi, Naveen
    Lodhi, Faisal Rashid
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2013, 63 (07) : 854 - 858
  • [33] Hormone receptors AR, ER, PR and growth factor receptor Her-2 expression in oral squamous cell carcinoma: Correlation with overall survival, disease-free survival and 10-year survival in a high-risk population
    Adnan, Yumna
    Ali, Syed Muhammad Adnan
    Awan, Muhammad Sohail
    Idress, Romana
    Awan, Muhammad Ozair
    Farooqui, Hasnain Ahmed
    Kayani, Hammad Afzal
    PLOS ONE, 2022, 17 (05):
  • [34] Mitochondrial DNA alterations correlate with the pathological status and the immunological ER, PR, HER-2/neu, p53 and Ki-67 expression in breast invasive ductal carcinoma
    Lin, Chen-Sung
    Chang, Shi-Chuan
    Ou, Liang-Hung
    Chen, Chien-Ming
    Hsieh, Sophie Swen-Wan
    Chung, Yu-Ping
    King, Kuang-Liang
    Lin, Shoei-Loong
    Wei, Yau-Huei
    ONCOLOGY REPORTS, 2015, 33 (06) : 2924 - 2934
  • [35] ENZYME-LINKED-IMMUNOSORBENT-ASSAY OF HER-2/NEU GENE-PRODUCT (P185) IN BREAST-CANCER - ITS CORRELATION WITH SEX STEROID-RECEPTORS, CATHEPSIN-D AND HISTOLOGIC GRADES
    MARSIGLIANTE, S
    MUSCELLA, A
    CIARDO, V
    BARKER, S
    LEO, G
    BAKER, V
    MOTTAGHI, A
    VINSON, GP
    STORELLI, C
    CANCER LETTERS, 1993, 75 (03) : 195 - 206
  • [36] Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience
    Kinsella, Mary Diane
    Nassar, Aziza
    Siddiqui, Momin T.
    Cohen, Cynthia
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2012, 5 (06): : 530 - 536
  • [37] Syndecan-1 could be added to hormonal receptors and HER2/neu in routine assessment of invasive breast carcinoma, relation of its expression to prognosis and clinicopathological parameters
    Soliman, Nahed A.
    Yussif, Shaimaa M.
    Shebl, Abdelhadi M.
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (05) : 977 - 982
  • [38] Interrelationships Between Ki67, HER2/neu, p53, ER, and PR Status and Their Associations With Tumor Grade and Lymph Node Involvement in Breast Carcinoma Subtypes Retrospective-Observational Analytical Study
    Shokouh, Taghipour Zahir
    Ezatollah, Aalipour
    Barand, Poorya
    MEDICINE, 2015, 94 (32)